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Reactivation of Myc transcription in the mouse
heart unlocks its proliferative capacity
Megan J. Bywater1,2, Deborah L. Burkhart 1, Jasmin Straube2, Arianna Sabò 3, Vera Pendino 4,
James E. Hudson2, Gregory A. Quaife-Ryan 2, Enzo R. Porrello5,6, James Rae7, Robert G. Parton 7,8,
Theresia R. Kress4, Bruno Amati 3, Trevor D. Littlewood 1, Gerard I. Evan 1,10✉ &
Catherine H. Wilson 1,9,10✉
It is unclear why some tissues are refractory to the mitogenic effects of the oncogene Myc.
Here we show that Myc activation induces rapid transcriptional responses followed by
proliferation in some, but not all, organs. Despite such disparities in proliferative response,
Myc is bound to DNA at open elements in responsive (liver) and non-responsive (heart)
tissues, but fails to induce a robust transcriptional and proliferative response in the heart.
Using heart as an exemplar of a non-responsive tissue, we show that Myc-driven tran-
scription is re-engaged in mature cardiomyocytes by elevating levels of the positive tran-
scription elongation factor (P-TEFb), instating a large proliferative response. Hence, P-TEFb
activity is a key limiting determinant of whether the heart is permissive for Myc transcrip-
tional activation. These data provide a greater understanding of how Myc transcriptional
activity is determined and indicate modification of P-TEFb levels could be utilised to drive
regeneration of adult cardiomyocytes for the treatment of heart myopathies.
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Myc is a basic helix-loop-helix–leucine zipper(bHLH–LZ) transcription factor that binds pre-ferentially to specific sequences in the genome, termed
E-boxes1, via association with its bHLH–LZ heterodimerisation
partner Max2–4. Myc functions principally as a transcriptional
activator by potentiating transcription initiation via association
with various cofactors, such as TRRAP and associated histone
acetyl-transferases5–7 and facilitating productive transcriptional
elongation by promoting RNA polymerase II (PolII) loading and
via its association with the positive transcription elongation factor
(P-TEFb)8–11. P-TEFb is comprised of CDK9 and Cyclin T1 that
are stringently regulated by various transcriptional and post-
transcriptional mechanisms12–15, and dynamically controlled by
an association with an inactivation complex comprised of 7SK
snRNA, Larp7, MEPCE and HEXIM16–18. P-TEFb phosphor-
ylates DSIF, NELF and serine 2 of the C-terminal domain (CTD)
of paused RNA PolII leading to productive elongation12–15.
Myc is a highly pleiotropic proto oncogene that coordinates
multiple transcriptional programmes underpinning normal cell
replication, differentiation, metabolism and apoptosis2,19–22.
Together with the dedicated role in controlling the growth and
division of normal cells, Myc also governs diverse cell extrinsic
processes required for tissue regeneration in a manner that is
tightly tailored to the tissue, in which Myc is activated23–25. Since
deregulated and elevated Myc expression is a pervasive and causal
attribute of most, perhaps all, tumours, understanding how tissue-
specific responses to Myc are determined at a molecular level is
imperative.
Comprehensive analysis of Myc transcriptional output in indi-
vidual cell types indicates that Myc regulates the expression of
thousands of genes, perhaps a third of the transcriptome26–32. Such
studies show great diversity across experimental platforms29,32 and
hint that components of the transcriptional repertoire of Myc are
highly context specific. In particular, genome-wide analysis of Myc
occupancy indicates the presence of Myc on virtually all promoters
with open chromatin26,27,30,33,34, suggesting that tissue-specific
variations in Myc activity arise by engagement of specific, pre-
configured resident cellular transcriptional programmes. However,
this large and diverse repertoire of potential Myc target genes, and
the lack of comparative analysis of transcriptional responses to Myc
in different tissues28–30, have together confounded reliable identi-
fication of common and tissue-specific Myc-dependent transcrip-
tional programmes. Moreover, recruitment of Myc to a given gene
does not always correlate with its level of transcription29,32, and
binding efficiency and transcriptional outputs are influenced sig-
nificantly by different levels of Myc expression31,35,36. Conse-
quently, both the precise mechanism as to how Myc targets genes
and what factors govern the transcriptional consequence of Myc
binding in differing tissue types remains unclear.
We show that Myc transcription is dependent on the level of
P-TEFb within a cell. Overexpression of both Myc and Cyclin T1
in the normally non-responsive heart facilitates Myc-driven
transcription and proliferation.
Results
Myc-driven proliferation is tissue restricted. To compare the
responses of different tissues to the acute activation of a similar level
of Myc, we generated a mouse strain in which supraphysiological
levels of the switchable Myc protein c-MycERT2 are ubiquitously
expressed from a common promoter at comparable levels across
tissues. In this knock-in mouse strain, the R26LSL-c-MycER locus
(R26MER)36 is modified to include a CAG (chicken beta actin/CMV)
enhancer that augments MycERT2 expression (Supplementary
Fig. 1a). R26CAG-LSL-c-MycERT2 mice were crossed into the Tg(Zp3-
cre)93Knw strain, in which Cre is active in the oocyte, efficiently
excising the LSL stop cassette in all adult tissues of the resultant
R26CMER mice37. Compared with the physiological level of Myc
expressed in R26MER/+ cells (heterozygous for the R26MER allele)36,
R26CMER/+ cells express around eightfold higher levels of MycERT2
RNA (Supplementary Fig. 1b) in each tissue tested. R26CAG-LSL-MER
and R26LSL-MER mice were interbred to generate an allelic series of
ascending levels of MycERT2 expression (R26+/+, R26LSL-MER/+,
R26LSL-MER/LSL-MER, R26CAG-LSL-MER/+, R26CAG-LSL-MER/LSL-MER
and R26CAG-LSL-MER/CAG-LSL-MER). To measure directly relative
levels of MycERT2 in this allelic series, mouse embryonic fibroblasts
(MEFs) were isolated from each strain and the LSL stop cassette
excised by infection in vitro with a Cre-expressing adenovirus to
engage constitutive MycERT2 expression. Western blot analysis of
cell lysates confirmed an ascending allelic series of MycERT2
expression, with homozygous R26MER and R26CMER cells expres-
sing twice the level of their respective heterozygous counterparts
(Fig. 1a). This allelic expression series was precisely mirrored in
tissues from heterozygous and homozygous R26CMER mice (Sup-
plementary Fig. 1c).
To rule out the possibility that high levels of Myc might
modulate the Rosa26 promoter—and hence elicit artefactual
feedback effects—we crossed R26CMER mice to mice carrying a
R26mTmG (Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo) reporter
allele38. Systemic activation of MycERT2 in R26CMER/mTmG mice
had no impact on expression of either Tomato or MycERT2
transcripts in any tested tissues (Supplementary Fig. 1d). Hence,
elevated MycERT2 activity does not modulate activity of the
Rosa26 promoter.
We next determined whether acute activation of MycERT2 elicits
a proliferative response in tissues of R26CMER/+mice. MycERT2 was
activated for 24 h by systemic administration of tamoxifen39 and
proliferation assessed by immunohistochemical staining of Ki67,
bromo-2′-deoxyuridine (BrdU) and the mitotic marker phospho-
histone H3 (p-H3). We observed a consistent pattern of proli-
ferative responses to supraphysiological Myc in tissues (Fig. 1b, c)
that fell into three general classes: (1) adult tissues, such as liver,
lung and pancreas with normally low levels of endogenous Myc
(Fig. 1d), but capable of significant regeneration after injury. Such
tissues showed a marked induction of proliferation upon Myc
activation. (2) Adult tissues, such as kidney, heart and brain, with
normally low levels of endogenous Myc and a limited capacity to
regenerate. In these, Myc elicited only a negligible rise in
proliferation. (3) Tissues with constitutively high proliferative rates
and substantial constitutive levels of endogenous Myc (Fig. 1d),
such as thymus and spleen, in which activation of ectopic Myc
elicited no significant additional proliferation above the already
high basal level. Neither sustaining MycERT2 activation for 3 days
nor increasing the expression level of MycERT2 from one to two
copies of R26CMER changed the proliferative responses to Myc in
any tissue (Supplementary Fig. 1e–h). Hence, different tissues
harbour different inherent sensitivities to Myc-driven proliferation.
Myc binding does not correlate with efficient transcription.
There are several plausible explanations for the failure of acute
Myc activation to induce a proliferative response in tissues, such
as heart and brain. First, non-responsive tissues might express
high levels of one or more of the Mxd proteins, which could
directly antagonise Myc’s transcriptional function by sequestering
Max and/or competing for its binding to shared target genes. To
investigate this possibility, we determined the levels of Mxd
expression in various tissues. Although expression of Mxd family
members varied across tissues (Supplementary Fig. 2a), we saw no
correlation between the extent of Myc-induced proliferation and
the levels of Mxd transcripts. Next, we determined whether Myc
is still able to bind its target genes using ChIP-sequencing analysis
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of Myc binding sites 4 h after activation in exemplar responsive
(liver) and non-responsive (heart) tissue. We observed a dramatic
increase in gene occupancy upon MycERT2 activation in both
tissues, from a few hundred sites in wild-type control, reflecting
the low levels of endogenous Myc expression in these tissues, to
~30,000 after Myc activation (Fig. 2a). Hence, the failure of the
heart to proliferate in response to Myc activation cannot be
attributed to the inability of ectopic Myc to access its target genes.
Around a quarter of Myc target binding sites were common to
both tissues, with a significant overlap principally at promoter
elements (Fig. 2b, c). Motif analysis demonstrated significant
enrichment for the E-box consensus sequences at these regions
(Fig. 2d) and gene ontology indicated that these overlapping
promoter binding sites located to ‘classic’ core Myc-dependent
genes implicated in control of gene expression, mRNA processing
and mitotic cell cycle (Fig. 2d). In addition to these shared targets,
however, Myc also bound discrete sets of promoter elements that
differed between the two tissues (Fig. 2b). These tissue-specific
sites were also enriched for E-box consensus sequences but
demonstrated a generally lower affinity for Myc in comparison to
the shared core elements (Fig. 2e, f). Interestingly, these tissue-
specific promoter elements were associated with genes whose
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expression defines each tissue (i.e., hepatocytes vs cardiomyocytes
respectively—Fig. 2e, f), consistent with the idea that Myc binds
already active/open promoters26,27,30,32–34. Myc ChIP-seq pro-
files, RNA PolII ChIP-seq in normal liver and heart, ATAC-seq in
purified cardiomyocytes40, publicly available data for chromatin
marks of active transcription (H3K27 acetylation H3K4 tri-
methylation and H3K4 mono-methylation) and DNAse-seq in
heart and liver41 all concurred that Myc binding closely overlaps
with transcriptionally active promoter and distal elements in each
tissue. This holds true across both common and tissue-specific
Myc-bound sites. For example, promoters bound in the heart but
not liver are characterised by absence of active chromatin marks
and RNA PolII binding in the liver. Conversely, promoters bound
by Myc only in liver lack active chromatin marks or associated
RNA PolII in heart (Fig. 3a, b, Supplementary Fig. 3a, b). To
confirm Myc binding to genes implicated in the transcriptional
control of cell cycle in the heart, liver and purified cardiomyo-
cytes, we performed sub analysis of Myc binding and open
chromatin marks in a mitotic cell cycle gene set (GO: 0000278).
Over 60% of these sites were marked as open and Myc bound
(Supplementary Fig. 3c, d). These data confirm that Myc binds
“open” chromatin at both promoters and distal sites (enhancers),
and that the disposition of chromatin accessibility to Myc is pre-
configured in a tissue-specific way. Together, these data indicate
that adult terminally differentiated heart retains an open chro-
matin architecture at sites required for Myc to drive transcrip-
tional control of proliferation and that the regenerative capacity
of the heart is lost due to the transcriptional control rather than
an epigenetic block.
Since Myc efficiently binds target gene DNA in both heart and
liver, we investigated other potential mechanism(s) that might
limit proliferative output in the non-responsive heart. We first
determined the overall transcriptional output in various tissues
(heart, kidney, liver and lung) of R26CMER/+ and R26+/+ control
mice, following acute Myc activation for 4 h. Differentially
expressed genes (DEGs) were called in each tissue based on the
fold change (FC) in mRNA levels between R26CMER/+ and R26+/+
control mice (Log2FC ≥ 0.5, q ≤ 0.05). In agreement with previous
observations28,30–32, the total number of DEGs in each tissue
(Fig. 4a, Supplementary Data 1) was much lower than the number
of Myc-bound promoters, albeit with significant inclusive overlap
(Fig. 4b). Comparison of DEGs in the liver, lung, kidney and heart
indicated considerable commonality among up-regulated genes
(Fig. 4c) implicated in prototypical core Myc-regulated processes,
such as ncRNA, rRNA and tRNA, metabolic processes (Fig. 4d).
By contrast, Myc-repressed genes showed very little overlap across
tissues, although gene ontology analysis did suggest that genes
overlapping in two or more organs favoured involvement in
negative regulation of cell movement, locomotion and migration
(Fig. 4e, f). Tissue-specific genes down-regulated by Myc showed
significant overlap with genes normally expressed within that
tissue, (Fig. 4g, Supplementary Data 2) and their functions were
generally associated with differentiated tissue-specific processes
(Fig. 4h, Supplementary Data 2).
Remarkably, DEG numbers also correlated well with each
tissue’s proliferative response to MycERT2 (Figs. 4a and 1b, c):
tissues with the lowest overall transcriptional changes displayed
the least proliferative responses. However, while activation of
ectopic Myc induced significant transcriptional changes in a
greater number of target genes in liver than in heart, quantitative
analysis of the RNA showed that most of the mRNAs that were
induced in liver also exhibited modest, if non-significant,
responses in the heart (Fig. 4i). Indeed, gene-set enrichment
analysis in the heart confirmed a significant trend in the increased
expression of common Myc targets, even when defined as targets
commonly up-regulated in response to Myc in all tissues,
excluding the heart (Fig. 4j). Hence, the transcriptional response
to activation of ectopic Myc in the heart is not absent but highly
attenuated and below that required to initiate cell proliferation.
This refractoriness of the heart transcriptome to Myc remained
evident even after prolonged (24 h) Myc activation or in response
to very high Myc levels (homozygous R26CMER mice; Supple-
mentary Fig. 4a, b).
Myc transcriptional output is limited by P-TEFb. The most
plausible explanation for our data is that the attenuated tran-
scriptional and biological response to Myc in heart is due to either
active transcriptional inhibition and/or insufficiency of requisite
transcriptional cofactors or machinery. Consistent with this, both
the total and phosphorylated levels of the CTD of RNA PolII
(Rpb1) were much lower in non-responsive heart and kidney than
in Myc-responsive tissues, such as the liver and lung (Fig. 5a).
Since recruitment of P-TEFb is necessary for transcriptional
elongation8–10, we next assessed the expression levels of the
components of P-TEFb–CDK9 and Cyclin T1. Surprisingly, both
CDK9 and Cyclin T1 proteins were present at considerably lower
levels in the heart and kidney compared with lung or liver, along
with components of the pause factors NELF and DSIF (Fig. 5a,
Supplementary Fig. 5a). Conversely, both Larp7, a negative reg-
ulator of P-TEFb, and the 7SK short non-coding RNA that serves
as the scaffold for the P-TEFb inactivation complex were relatively
more abundant in the heart and kidney (Fig. 5a, Supplementary
Fig. 5b). This intimated that the inability of Myc to elicit tran-
scriptional changes in the heart arises from a tissue-specific defi-
ciency in core transcriptional cofactors, notably P-TEFb and
RNA PolII itself, that are required for efficient transcriptional
initiation and elongation. Since paused RNA PolII is dependent
upon P-TEFb for progression42, we directly tested whether tran-
scriptional elongation is generally rate limiting for Myc-driven
transcription using the specific CDK9 inhibitor AZ5576 (Astra-
Zeneca) to inhibit P-TEFb in liver. Wild-type and R26CMER/+
mice were concurrently treated with 4-hydroxytamoxifen (4-OHT;
Fig. 1 The proliferative response to supraphysiological Myc is very variable across different tissues. a Immunoblot analysis of MycERT2 and endogenous
c-Myc protein levels in wild-type (R26+/+) mouse embryonic fibroblasts (MEFs) maintained in serum-deprived media, and at the indicated type points (in
hours) post addition of serum, all compared with asynchronous R26+/+, R26MER/+, R26MER/MER, R26CMER/+, R26MER/CMER and R26CMER/CMER MEFs.
Expression of actin is included as a loading control. Image represents the results from six individual mice. b Immunohistochemical and immunofluorescence
staining of Ki67 and BrdU in the brain, heart, kidney, lung, pancreas, liver, spleen and thymus isolated from wild-type (R26+/+) and R26CMER/+ mice 24 h
post administration of tamoxifen. Representative images based on analysis of five independent mice. Scale bar represents 50 μm. c Quantification of p-H3-
positive nuclei percentage from brain, heart, kidney, lung, pancreas, liver (hepatocytes), spleen (red pulp) and thymus isolated from oil-treated R26CMER/+
(n= 5 for heart, liver, lung, kidney, spleen and pancreas, and n= 3 for brain) mice or wild-type (R26+/+, n= 5 for heart, liver, lung, kidney and spleen, n= 4
for pancreas, and n= 3 for brain and thymus) and R26CMER/+ (n= 3) mice 24 h post administration of tamoxifen. Mean of five images per mouse; mean
and s.e.m shown. d Immunoblot analysis of MycERT2 and endogenous c-Myc expression in the brain, heart, kidney, lung, pancreas, liver, spleen and thymus
isolated from R26CMER/+ mice. Sample loading was normalised for equal protein content, as determined by a bicinchoninic acid assay. Expression of
GAPDH is included as a confirmation of efficient protein isolation. Representative results based on analysis of four independent mice.
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to activate MycERT2) and AZ5576, and livers collected 4 h later.
AZ5576 effectively inhibited CDK9 activity, as attested by a
decrease in phosphorylated Rpb1 levels (Fig. 5b) and, notwith-
standing the presence of active MycERT2, such inhibition of
CDK9 significantly attenuated transcription of Smpdl3b, Cad,
Gnl3 and Polr3g, genes regulated by Myc in multiple tissues
(Fig. 5c). Hence, inhibition of P-TEFb, and consequential
decreased phosphorylation of RNA PolII, renders liver non-
permissive for Myc response. The same was observed in MEFs
(Supplementary Fig. 5c, e). Conversely, ectopic overexpression of
Cyclin T1 in adult R26CMER/+ cardiomyocytes in vitro efficiently
abrogated their normal refractoriness to Myc and permitted effi-
cient expression of Myc target genes previously shown to be Myc
unresponsive in adult heart (Bzw2, Pinx1, Polr3d, St6 and Cdc25a;
Fig. 5d, e, Supplementary Fig. 5f, g). Together, these data support
the notion that transcriptional activity of Myc is limited by
P-TEFb availability. Further experiments would be required to
determine the mechanistic basis of this dependency.
Bp from Myc peak centre
Liver specific MYC-bound promoters:
Heart specific MYC-bound promoters:
0 1000–10000 1000–1000
Pos. Best site in sequence
–500
Liver: 
2264 Common: 
6778
Heart: 
2485
MYC-bound promoters:
142 230 23,837 34,343
39,26926,740900212
H
ea
rt
Li
ve
r
MYC-bound distal elements:
Common: 
2975
Liver: 
15,273
Heart: 
11,479
P
ro
ba
bi
lit
y
(×
10
3 )
P
ro
ba
bi
lit
y
(×
10
3 )
P
ro
ba
bi
lit
y
(×
10
3 )
2.0
1.0
0
0 500
A
ve
ra
ge
R
ea
d 
co
un
t
A
ve
ra
ge
R
ea
d 
C
ou
nt
A
ve
ra
ge
R
ea
d 
C
ou
nt
16
8
16
8 01
2+
Pos. Best site in sequence
–500
2.0
1.0
0
0 500
Pos. Best site in sequence
–500 0 500
#Ebox
Motifs:
#Ebox
Motifs:
Bp from Myc
peak centre
Bp from Myc
peak centre
0 1000–1000
8
4
Common
MYC
peaks:
10
5
0 1000–1000
Common
MYC
peaks:
Liver
specific
Heart
specific
a MYC ChIP-sequecing: b c
d
e
GO Biological Process
Gene set
Adj.
P-value
Z-score
Combined
score
Gene expression 1.12e–20 –2.34 107.46
mRNA processing 9.91e–10 –2.39 49.45
ncRNA metabolic process 1.13e–9 –2.33 48.02
Posttranscriptional regulation 
of gene expression 7.48e
–9 –2.46 46.06
RNA splicing 2.42e–8 –2.33 40.86
Regulation of translation 1.81e–6 –2.47 32.67
Mitotic cell cycle 4.02e–4 –2.22 17.35
Mouse Gene Atlas
Gene set
Adj.
P-value
Z-score
Combined
score
Liver 4.47e–110 –1.61 405.17
Kidney 3.07e–5 –1.48 15.36
Intestine 0.05 –1.50 4.64
Mouse Gene Atlas
Gene set
Adj.
P-value
Z-score
Combined
score
Skeletal muscle 9.11e–18 –1.70 66.28
Heart 1.3e–11 –1.72 43.18
Lung 1.23e–5 –1.47 16.62
R26+/+ R26CMER /+
Promoter
Intragenic
Intergenic
Common MYC-bound promoters:
f
MYC MA0147.3
p = 1.9e-92
Liver Heart
MYC MA0147.3
MYC MA0147.3
p = 1.2e-18
p = 1.9e-72
0
1
2+
2.0
1.0
0
3.0
Fig. 2 Myc binding differs between tissues. a The number of Myc peaks and their location (promoter, intragenic and intergenic). Replicates are derived
from independent mice. b Venn diagram of the overlap of peaks called within promoter regions (−2 kb to +1 kb from the nearest TSS). c Venn diagram of
the overlap of peaks called within distal elements. d Motif probability curves for common Myc-bound promoters show the probability of an E-box
consensus sequence occurring at a given position relative to the Myc ChIP peak at each common promoter site, as determined by CentriMo (top left).
Average read count of Myc peaks at common promoters containing 0, 1 or >2 E-box motifs within 1000 bp from the peak centre in liver and heart
chromatin (bottom left). Selected significant GO Biological Process Gene sets that overlap with common Myc-bound promoter elements (right). e Motif
probability curves for liver-specific promoters show the probability of an E-box consensus sequence occurring at a given position relative to the Myc ChIP
peak at each liver-specific promoter site, as determined by CentriMo (left). Average read count of Myc peaks shown at common (black) and liver-specific
(green) promoter sites (centre). Selected significant Mouse Gene Atlas Gene sets are shown that overlap with liver-specific Myc-bound promoter
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livers harvested from wild-type (R26+/+ n= 2) and R26CMER/+ (n= 2) mice at 4 h post administration of 4-OHT. MemeSuite Centrimo computed P-values
are derived by a binomial test. Enrichr computed P-value (Fisher’s exact test), Z-score (modified Fisher’s exact test to determine deviation from an
expected rank) and combined score (C=ln(P) × Z) are shown. Source data are provided as a Source Data file.
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Enabling Myc transcription in heart restores proliferation.
Expression of CDK9, Cyclin T1 and RNA PolII all progressively
decrease during post-natal cardiac maturation43. We therefore first
determined the extent of Myc-dependent transcriptional respon-
siveness in juvenile heart tissue. Unlike the adult heart, 15-day-old
juvenile hearts express levels of P-TEFb, RNA PolII comparable to
those in adult liver (Fig. 6a, Supplementary Fig. 6a, b). Acute (4 h)
MycERT2 activation in R26CMER/+ juvenile heart induced expres-
sion of a panel of common Myc transcriptional target genes (Bzw2,
Pinx1, Polr3d, St6 and Cdc25a) normally up-regulated by Myc in
the adult liver but not in adult heart (Fig. 6b). RNA sequencing
indicated a proficient global transcriptional response in juvenile
heart (1601 DEGs up-regulated and 1133 down-regulated; Fig. 6c,
Supplementary Data 3), with significant enrichment for common
Myc targets (Supplementary Fig. 6c), defined from the overlap of
genes up-regulated in response to the activation of Myc in all four
tissues (Fig. 4c). Following 24 h of tamoxifen treatment, juvenile
R26CMER/+ mice heart exhibited a marked proliferative response as
indicated by substantial induction of both G1 (Cdk4) and G2
(Cdk1/Ccnb1) cell cycle genes (Supplementary Fig. 6d), enrichment
of pro-cell cycle progression gene sets (Supplementary Fig. 6e) and
significant levels of mitosis (Fig. 6d). The extent of Myc-induced
cardiomyocyte proliferation was comparable to that observed in
tamoxifen-activated R26CMER/+ adult liver (Fig. 6d). To confirm
that Myc was acting to induce proliferation directly in cardio-
myocytes themselves, we restricted expression of MycERT2 to car-
diomyocytes using the Myh6Cre allele (Tg(Myh6-cre)2182Mds/J44,
in which Cre recombinase is driven from the Myh6 promoter that
directs expression of the Myosin heavy chain α isoform solely in
cardiomyocytes.Myh6Cre; R26LSL-CMER/+mice were generated and
at 15 days of age given a single bolus of tamoxifen to activate
MycERT2. Within 48 h, Myh6Cre; R26LSL-CMER/+ hearts displayed
both p-H3 and Ki67 positivity specifically in cardiac troponin T and
PCM1-positive cardiomyocytes, displayed aurora B kinase positivity
at centrally located mid-bodies (Fig. 7a, Supplementary Fig. 7a) and
had doubled in size compared with R26LSL-CMER/+ controls
(Fig. 7b, c). Overt cardiomyocyte division was evident from a 1.8-
fold increase in cardiomyocyte number without any discernible
change in cardiomyocyte size (Fig. 7c, d, Supplementary Fig. 7b–d).
To further confirm cytokinesis, transmission electron micrographs
(TEM) from Myh6Cre; R26LSL-CMER/+mice 48 h post tamoxifen
treatment were generated and 3D rendering used to identify car-
diomyocytes in mitosis and cytokinesis (Fig. 7e, Supplementary
Movies 1 and 2). Over the longer term, transient elevated MycERT2
activity in 15-day-old Myh6Cre; R26LSL-CMER/+ mice caused a large
increase in heart size and increased p-H3 immunoreactivity. Fur-
thermore, a large proportion of cardiomyocytes displayed dis-
assembled sarcomeres and mice did not survive beyond 4 days post
MycERT2 activation (Supplemental Fig. 7e).
To directly test if increasing P-TEFb levels within cardiomyocytes
of the adult heart in vivo is permissive for efficient Myc
transcriptional activation and proliferation, we infected wild type,
R26CMER/+, Myh6Cre; R26LSL-CMER/+ and R26LSL-CMER/+ mice
with an adeno-associated virus directing ectopic expression of Cyclin
T1 (encoded by Ccnt1) or RFP under the troponin T promoter
specifically in cardiomyocytes. After 4 weeks, we confirmed viral
Cyclin T1 overexpression in 34% of cardiomyocytes by immuno-
histochemistry (Fig. 8a). As described previously43,45 and confirmed
here, elevated expression of Cyclin T1 in cardiomyocytes led to an
increase in CDK9 and phosphorylated RNA PolII (S2; Fig. 8b).
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Acute MycER activation in the presence of overexpressed Cyclin T1
induced the transcription of a panel of common Myc target genes
normally up-regulated by Myc in the liver but not in the adult heart
(Fig. 8c, Supplementary Fig. 8a). RNA sequencing indicated a
proficient global transcriptional response to the activation of Myc in
the presence of ectopic Cyclin T1 in the adult heart or purified
cardiomyocytes (Supplementary Data 4 and 5), with positive
enrichment for common Myc targets and pro-cell cycle progression
gene sets (Supplementary Fig. 8b). Positive enrichment of common
Myc targets was also observed in cardiomyocytes purified from
Ccnt1-infected Myh6Cre; R26LSL-CMER/+ hearts vs uninfected
Myh6Cre; R26LSL-CMER/+ hearts 4 h post activation of Myc (Fig. 8d).
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A short pulse of MycERT2 activation in combination with Cyclin T1
overexpression resulted in a marked proliferative response in hearts
collected at 48 h post a single dose of tamoxifen, cardiomyocytes
displaying markers of cell cycle, mitosis, cytokinesis (Fig. 9a, b,
Supplementary Fig. 9a, b), expression of mitosis and cytokinesis gene
sets (Supplementary Fig. 9c, Supplementary Data 6), increased heart
size (Fig. 9c, d, Supplementary Fig. 9d). At 72 h post MycERT2
activation in combination with Cyclin T1 overexpression heart size
was further increased along with increased cardiomyocyte number,
but without any measurable change in cardiomyocyte size
(Fig. 9c–e) or nucleation (Supplementary Fig. 9e). A single
transient burst of MycERT2 activity in Cyclin T1 expressing
Myh6Cre; R26LSL-CMER/+ adult cardiomyocytes was compatible
with long-term survival, with no histological abnormalities
detected at 28 days after MycERT2 activation (Supplementary
Fig. 9f). Collectively, these data illustrate that Myc transcriptional
activity can be facilitated in adult cardiomyoctes by co-activation
of the transcriptional co-factor P-TEFb, thus enabling adult heart
tissue to re-enter the cell cycle.
Discussion
Myc is widely acknowledged to play a pivotal coordinating role in
the transcriptional control of somatic cell proliferation and tissue
regeneration, and its activity is deregulated and typically elevated
in the majority of aggressive cancers2,21,22. Past studies have
largely focused on identifying Myc transcriptional programmes
that are common across cell types. However, Myc exhibits great
cell type variability, both with respect to how efficiently it can
drive cell proliferation and the phenotypes its activities elicit in
different tissues23,25,46,47. We developed a unique mouse model
whereby a switchable variant of Myc is driven at a comparable
and defined oncogenic level from an augmented version of the
endogenous Rosa26 promoter in target cells. The variant, aug-
mented Rosa26 promoter incorporates an additional CAG (CMV
and β-actin promoter elements) that increases the expression
level of Myc to supraphysiological levels frequent in many can-
cers. Unlike most tissue-specific promoters used to drive trans-
genic oncogenes, neither Rosa26 nor RosaCAG promoters are
repressed by Myc activation, obviating a major confounding
artefact in most conventional transgenic models. Replacing Myc
with the well validated, rapid and reversible switchable 4-OHT-
dependent MycERT2 variant allows the analysis of the immediate
and direct impact of Myc on its target genome48,49. Inclusion of
tissue-specific regulation via a Cre recombinase-excisable tran-
scriptional STOP element provides the option for tissue restricted
MycERT2 expression.
Using proliferation as the phenotypic signature of Myc output,
we identified three general classes of response to activation of
oncogenic levels of Myc: tissues that proliferated in response to
MycERT2 activation; tissues that did not; and tissues that exhib-
ited innately high endogenous Myc and proliferative indices. The
correlation between proliferative response to ectopic Myc in these
tissues (Fig. 1b, c) and the innate regenerative potential of each
tissue is striking and suggests an underlying mechanistic
connection50.
ChIP-seq analysis 4 h post MycERT2 activation in exemplar
Myc-responsive vs non-responsive tissues (respectively, liver and
heart) showed a dramatic increase in gene occupancy by Myc in
both tissues. Hence, tissue non-responsiveness to Myc is not due
to failure of ectopic Myc to access its chromatin targets. On the
contrary, we found striking similarities between the numbers of
sites to which Myc is bound across the different tissues analysed,
underscoring that the phenotypic outcome effected by Myc is not
solely dictated at the level of recruitment to chromatin. The
significant overlap in Myc-bound promoter regions across both
the liver and heart affirms the widely held notion that Myc binds
a discrete set of target genes common to multiple cell types and
implicated in governing core processes required for cell growth
and cell cycle progression. Nonetheless, Myc also binds a set of
promoter elements specific to each tissue, indicating that the
overall Myc-dependent cistrome is cell type specific. We also note
that this tissue-specific Myc binding repertoire is characterised by
the presence of chromatin marks indicative of open chromatin, in
keeping with the findings of others26,27,30,32–34.
Interestingly, as early as 4-h post Myc activation, we clearly see
a significant number of genes to be transcriptionally repressed.
These repressed genes principally articulate differentiated cell
type functions and show very little overlap between tissue types.
Moreover, around a third (34%) of the repressed genes appear to
be indirect targets, since Myc is not detected at their promoters
(Fig. 4b). Suppression of differentiation-specific genes by onco-
genic Myc has been widely observed irrespective of cell or tissue
type and is an example of the robust inverse generic relationship
between cell proliferation and differentiation51.
It has been proposed that stringent normalisation strategies
employed in the analysis of bulk RNA sequencing data can mask
the more global impact of Myc on transcription that might be
predicted from its promiscuous binding to open chromatin26,27.
Such general amplification is in no way excluded by our analyses.
Nonetheless, it is clear that the magnitude of transcriptional
change that the activation of ectopic Myc can instruct is sig-
nificantly limited in tissues that lack regenerative potential, like
the heart.
Fig. 4 Myc-directed transcriptional targets differ between tissues. a The number of differentially expressed genes (DEGs) between organs. b Venn
diagram depicting overlap of peaks within promoter regions identified by c-Myc ChIP sequencing from heart (red) or liver (green) isolated from R26CMER/+
mice together with genes differentially expressed in response to Myc (UP DEGs—black, DOWN DEGs—grey). Areas are proportional to the numbers of
promoters or DEGs within each cohort. c Venn diagram depicting numbers of genes showing increased expression in response to Myc (UP DEGs) in the
kidney (yellow), liver (green), lung (blue) and heart (red); (FDR < 0.05 and abs(log2FC) > 0.5). d Six most significant GO Biological Process Gene sets that
overlap with listed genes, showing a differential increase in expression (UP DEGs) in two or more tissues (kidney, liver, lung and heart). e Venn diagram
depicting numbers of genes showing decreased expression in response to Myc (DOWN DEGs) in the kidney (yellow), liver (green), lung (blue) and heart
(red). f Six most significant GO Biological Process Gene sets that overlap with listed genes that show a differential decrease in expression (DOWN DEGs)
in two or more tissues (kidney, liver, lung and heart). g Three most significant Mouse Gene Atlas Gene sets that overlap with listed genes that show a
differential decrease in expression (DOWN DEGs) only in the liver (liver specific). h Six most significant GO Biological Process Gene sets that overlap with
listed genes that show a differential decrease in expression (DOWN DEGs) only in the liver (liver specific, absent in kidney, heart and lung). i Heatmap
showing the union of DEGs called in each tissue; liver, lung, kidney and heart. Shown are mRNA expression fold changes (Log2) upon MycERT2 activation
relative to wild type. j Hearts isolated from R26CMER/+ mice show enrichment of common Myc targets (exclusive to the liver, lung and kidney) in
comparison to wild type (R26+/+). All analysis determined by RNA sequencing performed in the heart (n= 5), kidney, lung and liver (n= 3) of R26CMER/+
compared to wild-type (R26+/+) mice at 4 h post administration of 4-OHT. Enrichr computed P-value (Fisher’s exact test), Z-score (modified Fisher’s
exact) and combined score (C = ln(P) × Z) are shown.
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A simple hypothetical explanation for the pervasive suppres-
sion of differentiation by Myc is that certain essential components
of the transcriptional machinery, such as P-TEFb or even total
levels of Rbp1, available for loading onto promoters are limiting
and that repression of differentiation-specific genes is a mere
consequence of these limiting factors’ being redeployed to Myc
target genes, as recently proposed in 3T3 fibroblasts11. Analogous
scarcities in transcriptional machinery could also explain why
some tissues fail to respond transcriptionally to Myc. We
observed that both total and phosphorylated levels of Rpb1 are
significantly lower in the adult heart in comparison to the liver
(Supplemental Fig. 6b). However, we presume that the levels of
Rpb1 are sufficient to allow the transcription of genes required to
maintain heart function. Indeed, when we performed RNA PolII
ChIP sequencing in the adult heart, we detected heart-specific
genes loaded with significant amounts of RNA PolII. There are
several potential mechanisms that may concentrate the available
RNA PolII at specific locations. First, it is possible that the gen-
eration of “transcriptional hotspots” might concentrate essential
factors at the relevant genes52. Second, transcription in the pre-
sence of low Rpb1 may be aided by tissue-specific super enhan-
cers that recruits a large portion of the enhancer-associated RNA
PolII and its associated cofactors and chromatin regulators53,
unfortunately, testing of these hypotheses lies outside the scope of
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Fig. 5 Inhibition or overexpression of P-TEFb modulates efficiency of Myc-driven transcription. a Immunoblot analysis of the C-terminal domain (CTD)
of RNA Polymerase II—total (Rpb1) and phosphorylated (p-Rpb1(S5) and p-Rpb1(S2)), CDK9, Cyclin T1 and Larp7 expression in the heart, liver, lung and
kidney isolated from wild-type (R26+/+) mice. The composite figure is generated from the same samples loaded across multiple blots and a representative
image for GAPDH is shown. b Immunoblot analysis of the CTD of RNA Polymerase II, phosphorylated (p-Rpb1(S2)), and MycERT2 protein expression in
wild type (R26+/+) or R26CMER/+ livers, isolated 4 h post administration of 4-OHT either alone (4-OHT) or in combination with 60mg/kg AZ5576
(4-OHT+AZ5576). c Quantitative RT-PCR analysis of Smpdl3b, Cad, Gnl3 and Polr3g in wild type (R26+/+) and R26CMER/+ livers, isolated 4 h post
administration of 4-OHT (n= 6 R26+/+, n= 3 R26CMER/+) either alone or in combination with 60mg/kg AZ5576 (4-OHT+AZ5576, n= 4). Expression
is relative to the respective wild type (R26+/+). Mean and s.d shown. Two-way ANOVA with Tukey’s multiple comparisons test; R26+/+ vs 4-OHT: ***P=
0.001 (Smpdl3b, Cad, Gnl3 and Polr3g), R26CMER/+ 4-OHT vs 4-OHT+AZ5576: ***P= 0.001 (Smpdl3b, Cad and Gnl3), **P≤ 0.01 (Polr3g). d Immunoblot
analysis of Cyclin T1 and phosphorylated CTD of RNA polymerase II (p-Rpb1(S2)) in R26CMER/+ primary cardiomyocytes infected with an adenovirus
encoding either GFP (Ad-GFP) or Ccnt1 (Ad-Ccnt1). Replicate samples are derived from independent primary cardiomyocyte isolations. e Quantitative RT-
PCR analysis of Cad, Bzw2, Pinx1, Polr3d, St6 and Cdc25a in wild type (R26+/+, n= 5 except Pinx1 where n= 4 for Ad-GFP control) and R26CMER/+ (n= 5
except St6 where n= 4 for Ad-GFP control) primary cardiomyocytes infected with an adenovirus encoding either GFP (Ad-GFP) or Ccnt1 (Ad-Ccnt1), 4 h
post addition of 100 nM 4-OHT. Expression is relative to an individual wild type (R26+/+) Ad-GFP control. Mean and s.d shown. One-way ANOVA with
Tukey’s multiple comparisons test; Ad-GFP R26+/+ vs R26CMER/+: *P= 0.05 (Cad), Ad-Ccnt1 R26+/+ vs R26CMER/+: *P= 0.05 (Cad, Pinx1, Polr3d and St6)
**P= 0.01 (Bzw2 and Cdc25a). Replicate samples are derived from independent primary cardiomyocyte isolations and independent mice. Source data are
provided as a Source Data file.
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this manuscript. Myc has been shown to modify both RNA PolII
loading and its phosphorylation by P-TEFb (refs. 8–12,42,54). We
showed that responsiveness of individual tissues to Myc correlates
with the levels of expression of the basal transcription factors, P-
TEFb and RNA PolII, the pause factors, DSIF and NELF, and,
inversely, with the expression of the P-TEFb repression complex.
Adult mammalian heart is a prototypical, terminally differ-
entiated55, Myc non-responsive tissue in which Cyclin T1 is known
to be a limiting transcriptional regulator, and whose chronic
ectopic overexpression elicits promiscuous RNA polymerase
activity and cardiac hypertrophy43,56. While P1 neonatal heart
retains proliferative potential, this rapidly declines after birth and is
largely lost by P7 (refs. 57–59). This decline in neonatal cardiac
proliferative potential correlates with down-regulation of multiple
genes involved in cell cycle40,55,60–63, including endogenous Myc,
which is high at P1 but significantly reduced by P5 (Supplementary
Fig. 6a). Although changes in microRNAs (refs. 59,64), modulation
of the Hippo pathway65,66, and wholesale metabolic switching
from glycolysis to oxidative phosphorylation67,68 have all been
implicated, the mechanism underlying post-natal cardiac matura-
tion and loss of regenerative potential remains unknown. Inter-
estingly, both neonatal mouse heart and the zebrafish larval heart
express high levels of P-TEFb. However, whereas the zebrafish
adult heart retains 70% of its larval levels of P-TEFb and remains
competent to regenerate throughout development, P-TEFb levels in
the non-regenerative adult mouse heart drop by 85% (refs. 43,69).
Little is known regarding the regulation of P-TEFb during mam-
malian cardiac development. Levels of Cyclin T1 are regulated at
both transcriptional and post-transcriptional levels12–15, with
mitogens and cytokine signalling known to increase Cyclin T1
protein stability70,71. We and others have shown that the level of
Cyclin T1 is the key factor regulating the level and activity of P-
TEFb within cardiomyocytes43,45. Oncogenic Ras signalling
increases Cyclin T1 in the heart, leading to cardiac hypertrophy56.
It is tempting to speculate that the noted oncogenic cooperation
between Ras and Myc may, in part, arise through Ras-dependent
induction of P-TEFb, so promoting the efficiency of Myc-driven
transcription.
Re-establishing regenerative proliferation in the adult heart has
proven very difficult. Inhibition of Hippo signalling, enforced
expression of both G1 (CDK4 and Ccnd1) and G2/M (CDK1 and
Ccnb1) factors, and hypoxia all elicit modest regeneration66,72–74,
but at levels well below those of P1 neonatal heart. While the
adult heart is refractory to Myc-induced proliferation, enforced
ectopic Myc expression during neonatal life did extend the win-
dow of neonatal cardiomyocyte proliferation up to around P15, a
period that that coincides with high endogenous cardiac P-TEFb
expression. The large increase in cardiomyocyte number and
aurora B localisation to centrally located mid-bodies suggests that
cardiomyocytes isolated from juvenile mice can progress through
the cell cycle and many can complete cytokinesis. Remarkably, we
show that an increase in the level of P-TEFb in the adult heart is
sufficient to support ectopic Myc-dependent transcription, pro-
liferation and cytokinesis of cardiomyocytes in vivo, resulting in
increased heart size and cardiomyocyte number within a very
short timeframe. Importantly, this transient wave of proliferation
induced in a smaller fraction of total cardiomyocytes than in
juvenile mice is compatible with long-term survival. It will be of
great interest to determine if this genetic combination will prove
beneficial in models of cardiac injury.
Despite the significant changes in regenerative capacity and
responsiveness to Myc that attend cardiac development from
embryonic stem cells through mesoderm to precursor cardio-
myocyte to cardiomyocyte, the chromatin status at promoters for
genes involved in basic cellular function, including cell cycle reg-
ulation, show very little variation75,76. Similarly, the Myc binding
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Fig. 6 The juvenile heart is permissive to Myc-driven transcriptional
activation. a Immunoblot analysis of the C-terminal domain of RNA
polymerase II, total (Rpb1) and phosphorylated (p-Rpb1(S2)), Cyclin T1 and
CDK9 protein expression in wild-type heart and liver isolated from 15-day-old
(15d) and 60-day-old (60d) mice. Replicate samples are derived from
independent mice. b Quantitative RT-PCR analysis of Cad, Bzw2, Pinx1, Polr3d,
St6 and Cdc25a expression in wild-type (R26+/+) and R26CMER/+ heart
isolated from 15-day-old (15d, Bzw2 and Cad n= 6, Cdc25a, Pinx1, Polr3d and
St6 n= 7) mice vs heart (Bzw2, R26+/+ Pinx1 and R26CMER/+ Cad n= 9,
Cdc25a, Polr2d, St6, R26+/+ Cad and R26CMER/+Pinx1 n= 8, R26CMER/+ St6
n= 7, R26CMER/+ Cdc25a, Polr3d n= 6) and liver (R26+/+ Bzw2, Pinx1, Cad,
Cdc25a and St6 n= 9, R26+/+ Polr2d n= 8, R26CMER/+ Cad n= 10, R26CMER/+
Bzw2 n= 8, R26CMER/+ St6 n= 7, R26CMER/+ Cdc25a, Pinx1, Polr3d n= 6)
isolated from 60-day-old (60d) mice 4 h post administration of 4-OHT.
Expression is relative to the respective wild type (R26+/+). Mean and s.d
shown. One-way ANOVA with Tukey’s multiple comparisons test; 15 day
R26+/+ 4-OHT vs R26CMER/+ 4-OHT: ***P=0.001 (Cad, Bzw2, Pinx1, St6 and
Cdc25a), 15 day R26+/+ 4-OHT vs R26CMER/+ 4-OHT: **P=0.001 (Polr3d),
adult heart R26+/+ 4-OHT vs R26CMER/+ 4-OHT: ***P=0.001 (Cad), adult
liver R26+/+ 4-OHT vs R26CMER/+ 4-OHT: ***P=0.001 (Cad, Bzw2, Pinx1,
St6 and Cdc25a). Replicate samples are derived from independent mice.
c Heatmap showing the union of DEGs called in each tissue; adult liver (n= 3),
adult heart (n= 5) and 15-day-old (15d) heart. mRNA expression fold changes
(Log2) upon MycER activation are shown relative to wild type, as determined
by RNA sequencing of R26CMER/+ (n= 3) tissues relative to wild type
(R26+/+, n= 3) at 4 h post administration of 4-OHT. d Quantification of
p-H3-positive nuclei percentage in heart (positive cardiomyocyte nuclei only)
and liver (positive hepatocyte nuclei only) isolated from 15-day-old (15d) and
60-day-old (60d) wild-type (R26+/+, n= 10 15d, n= 8 60d) and R26CMER/+
(n= 4) mice 24 h post administration of tamoxifen. Means are taken from five
images per mouse; mean and s.d. shown. One-way ANOVA with Tukey’s
multiple comparisons test; R26+/+ 4-OHT vs R26CMER/+ 4-OHT: ***P=
0.001 (15-day heart and adult liver). Source data are provided as a Source
Data file.
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sites of the adult liver (proliferative) and the adult heart (non-
proliferative) exhibit significant overlap, indicating that even after
its maturation, adult, terminally differentiated heart retains an
open chromatin architecture at sites required to drive transcrip-
tional control of proliferation. Hence, if Myc could be induced by
mitogenic stimulus in the heart, cardiac epigenome architecture
does not preclude heart regenerative capacity: rather, it is the
inability of Myc to drive transcriptional output from regenerative
target genes (due to lack of the P-TEFb) that thwarts cardiomyo-
cyte proliferation.
Overall, our data indicate that tissue regenerative capacity is
tightly linked to the capacity of that tissue to respond to Myc and
that tissue Myc responsiveness is governed principally by
availability of key components of the core transcriptional
machinery, which Myc co-opts to drive its regenerative biological
output. However, in addition to its core target genes, which are
common across tissues, a significant number of its targets are
expressed in a tissue-specific manner. By contrast, tissue-specific
accessibility of target genes to Myc appears to be dictated prin-
cipally by hard-wired, tissue-specific epigenome organisation.
Our current study focuses in the main on liver and heart as,
respectively, prototypical examples of regenerative and Myc-
responsive vs non-regenerative and Myc-unresponsive tissues.
However, it seems reasonable that our findings could be extra-
polated more generally to offer insights into both regenerative
medicine and cancer susceptibility.
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Fig. 7 The juvenile heart is permissive to Myc-driven proliferation. a Immunofluorescent staining of cardiac troponin, p-H3, Ki67, PCM1, wheat germ
agglutinin and aurora B-positive mid-body in the heart of 15-day-old control (no cre) and Myh6-Cre; R26LSL-CMER/+ (cre+) mice. Representative images
based on analysis of five independent mice. Scale bar represents 10 μm. b Image of the whole heart and a tibia isolated from a 15-day-old control (no cre)
and Myh6-Cre; R26LSL-CMER/+ (cre+) mice. Scale bar represents 10mm. Representative images based on analysis on 21 independent mice. c The weight
(mg) of hearts (left, R26LSL-CMER/+; no cre, vehicle= 9, no cre tamoxifen= 11; R26LSL-CMER/+; cre+ vehicle n= 7, cre+ tamoxifen n= 10) and quantification
of the number of cardiomyocytes (right) isolated from 15-day-old control (no cre, vehicle= 3, no cre tamoxifen= 4) and Myh6-Cre;R26LSL-CMER/+ (cre+
vehicle n= 6, cre+ tamoxifen n= 7) mice post administration of tamoxifen or oil (veh), expressed as fold change over the length (mm) of a tibia isolated
from the same mouse. Mean and s.e.m. shown. One-way ANOVA with Tukey’s multiple comparisons test; vehicle cre vs tamoxifen cre+, vehicle no cre vs
tamoxifen cre+, tamoxifen no cre vs tamoxifen cre+ ***P= 0.001 (weight). Vehicle cre vs tamoxifen cre+ **P= 0.01, vehicle no cre vs tamoxifen cre+,
tamoxifen no cre vs tamoxifen cre+ ***P= 0.001 (cardiomyocyte number). Replicate samples are derived from independent mice. d Flow cytometry
quantification of p-H3 in cardiac troponin T-positive cardiomyocytes (left) and immunofluorescent staining (right) of cardiac troponin T (green), p-H3
(red) and DNA (blue) from 15-day-old control (no cre, n= 4) and Myh6-Cre; R26LSL-CMER/+ (cre+, n= 7) mice. Mean and s.d. shown. Unpaired t-test; no
cre vs cre+ ***P= 0.0006. Replicate samples are derived from independent mice. Scale bar represents 50 μm. e Three-dimensional render (second from
left) generated from 500 image z-stack (50 µm) of transmission electron micrographs from a Myh6-Cre; R26LSL-CMER/+ heart. Green shows outline of cells,
blue shows nuclei, pink line shows site of cross section through cells, outlined in green (second from right) and expanded (right). Imaging performed on a
single heart. Left image shows mitotic nuclei, arrow. Structures are indicated; f, myofibrils; n, nucleus; m, mitochondria; bv, blood vessel. Scale bars
represent 5 μm. All analysis 48 h post administration of tamoxifen. Source data are provided as a Source Data file.
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Methods
Mice and mouse maintenance. All experimental procedures received ethical
approval and were conducted in accordance with the Home Office UK guidelines,
under project licences 70/7586, 80/2396 (G.I.E.), which were evaluated and
approved by the Animal Welfare and Ethical Review Body at the University of
Cambridge. All animals were kept under SPF conditions. Mice were maintained on
regular diet in a pathogen-free facility on a 12 h light/dark cycle with continuous
access to food and water. Mouse strains, Tg(Zp3-cre)93Knw, Gt(ROSA)26Sortm4
(ACTB-tdTomato,-EGFP)Luo and Tg(Myh6-tTA)6Smbf/J were obtained from the Jackson
Laboratory. For generation of the R26CAG-LSL -c-MycER mice, MycERT2-IRES-eGFP
cDNA was cloned into pBigT, and then into the pROSA26CAG-PAS vector77 to
create the final R26CAG-LSL-c-MycER targeting vector. This vector was then linearised
and introduced into mouse embryonic stem cells. Germ-line transmission was
confirmed by PCR and verified by Southern analysis. Adult animals requiring
4-OHT were either i.p. injected with 1 mg (Z)-4-OHT (Sigma, H7904) in 10%
ethanol and vegetable oil (5 mg/ml), and collected 4 h post injection or with 1 mg
tamoxifen (Sigma, T5648) in 10% ethanol and vegetable oil (10 mg/ml) twice over a
24-h period and collected at 24–72 h post initial i.p. injection. Adolescent animals
were given 0.5 mg of either 4-OHT or tamoxifen per injection. For 48 or 72-h
collection points, mice were i.p. injected once with either 0.5 mg (adolescent) or
1 mg (adult) tamoxifen in 10% ethanol and vegetable oil. 5-BrdU (Sigma, B9285)
was administered by i.p. injection (100 µl, 10 mg/ml) 2 h before culling. AZ5576
was administered to mice at 60 mg/kg in 20% Captisol® Solution by oral gavage.
Mouse genotyping. Ear biopsies were collected from 2–5-week-old mice and
digested overnight at 55 °C in 10% Chelex 100 Resin (Bio-Rad Catalogue #142-
1253), 0.1 % Tween-20 and 0.25 mg/ml Proteinase K (Sigma P8044). A typical PCR
reaction was performed using GoTaq (Promega) with 1 µl of Chelex extracted
gDNA following manufacturers’ instructions. The following PCR conditions were
applied: 5 min, 95 °C initial denaturation; 35 cycles of 30 s at 95 °C, 30 s at 60–65 °C
and 1.5 min at 72 °C, followed by a final 5 min at 72 °C. PCR amplification
products were analysed by agarose gel electrophoresis. General primers for
Rosa26CAG were used to detect R26CMER and R26mTmG alleles, were universal
forward: 5′-CTCTGCTGCCTCCTGGCTTCT-3′ wild-type reverse: 5′-CGAGG
CGGATCACAAGCAATA-3′ and CAG reverse: 5′-TCAATGGGCGGGGGTCG
TT-3′. General primers for Rosa26 used to detect the R26MER allele were R26F:
5′-AAAGTCGCTCTGAGTTGTTAT-3′ R523: 5′- GGAGCGGGAGAAATGGATA
TG-3′ and R1295: 5′-GCGAAGAGTTTGTCCTCAACC-3′. Generic primers to
recognise Cre were Cre1: 5′-GCTGTTTCACTGGTTATGCGG -3′ and Cre2:
5′-TTGCCCCTGTTTCACTATCCAG -3′.
Mouse embryonic fibroblasts. MEFs were generated from embryos 13.5 d.p.f.
and cultured in DMEM (Thermo Fisher 41966052) supplemented with
penicillin–streptomycin (Thermo Fisher, 15140-122), L-glutamine (Thermo Fisher,
25030-024) and 10% BGS (Hyclone SH30541.03HI). All experiments were per-
formed between passage 3 and 5. For experiments, MEFs were plated at 5 × 105
cells per 6 cm culture dish in 10% BGS (where appropriate, plus adenovirus). To
render cells quiescent, the next day cells were washed twice with PBS and cultured
in media containing 0.1% BGS for 48 h. After 48 h serum deprivation, cells were
treated with 100 nM (Z)-4-OHT (Sigma, H7904) in ethanol to activate MycERT2
and 1 µM AZ5576 (AstraZeneca) in DMSO to block CDK9 and RNA, or protein
harvested 4 h later or cell cycle analysis performed after 16 h.
Cardiomyocyte purification and culture. Cardiomyocytes CMs were isolated
from adult mouse hearts (8–10 weeks of age) using a simplified Langendorff-free
method78 and cultured in M199 (Sigma, M4530) supplemented with 0.1% BSA
(supplier, number), 1X ITS Liquid Media Supplement (Sigma, I3146), 10 mmol/l
BDM (Sigma, B0753), 1X Chemically Defined Lipid Concentrate (Fisher,
11548846) and penicillin–streptomycin (Thermo Fisher, 15140-122). When nee-
ded, adenovirus was administered to CMs in culture media immediately after
removal of plating media. Medium was then replaced after 24 h with culture media
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Fig. 8 Overexpression of Cyclin T1 in the adult heart facilitates Myc-driven transcription in adult cardiomyocytes. a Immunohistochemistry (left) and
quantification (right) of Cyclin T1 in the liver isolated from adult R26CMER/+ or heart isolated from Myh6-Cre; R26LSL-CMER/+ mice systemically infected
with adeno-associated virus (serotype 9, 1 × 1011 vg/mouse) encoding either RFP (AAV9-RFP, n= 5) or Ccnt1 (AAV9-Ccnt1, n= 4) 4 weeks post infection.
Mean and s.e.m shown. Unpaired t-test; AAV9-RFP vs AAV9-Ccnt1: ***P < 0.0001. Representative images based on analysis of five independent mice.
b Immunoblot analysis of the C-terminal domain of phosphorylated RNA polymerase II (p-Rpb1(S2)), CDK9 and Cyclin T1 expression in the heart isolated
from adult Myh6-Cre; R26LSL-CMER/+ mice systemically infected with adeno-associated virus encoding either RFP (AAV9-RFP) or Ccnt1 (AAV9-Ccnt1)
4 weeks post infection. Replicate samples are derived from independent mice. c Quantitative RT-PCR analysis of Cad, Bzw2, Pinx1, Polr3d, St6 and Cdc25a
expression in control (R26LSL-CMER/+; no cre, n= 5) and Myh6-Cre; R26LSL-CMER/+ (R26LSL-CMER/+; cre+, n= 7) adult mouse heart isolated 4 weeks post
systemic infection with an adeno-associated virus encoding Ccnt1 (AAV9-Ccnt1) and 4 h post administration of 4-OHT. Expression is relative to the
respective wild type (R26LSL-CMER/+). Mean and s.e.m shown. Unpaired t-test; no cre vs cre+: ***P < 0.0005 (Cad, Bzw2, Pinx1 and St6), **P= 0.0013
(Cdc25a), **P= 0.0035 (Polr3d). Replicate samples are derived from independent mice. d Enrichment of common Myc targets (liver, lung, kidney and
heart) in cardiomyocytes isolated from the heart of AAV-CCNT1 infected Myh6-cre; R26LSL-CMER/+ (Myc+Cyclin T1) mice in comparison to uninfected
Myh6-cre; R26LSL-CMER/+ mice (Myc) at 4 h post administration of 4-OHT, as determined by RNA sequencing. Including normalised enrichment score
(NES) and FDR q-value (FDR).
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together with 100 nM (Z)-4-OHT (Sigma, H7904) in ethanol and collected after 4 h
for RNA extraction.
Adenovirus-mediated infections. Ad5CMVeGFP (VVC-U of Iowa-1174) was
obtained from the University of Iowa, Viral Vector Core and supplied at 3 ×
101 pfu/ml. For MEFs, 0.5 µl of virus was used per 5 × 105 cells. For CMs, 0.25 µl of
virus was used per 2 × 104 cells. Ad-RFP-mCCNT1 (ADV-223024) was obtained
from Vector Biolabs and supplied at 5.6 × 1010 pfu/ml. For MEFs, 20 µl of virus was
used per 5 × 105 cells. For CMs, 10 µl of virus was used per 2 × 104 cells. AAV9-
cTnT-3xFLAG-mCCNT1-WPRE and AAV-cTnT-RFP-WPRE (cat. no: VB5443)
were obtained from Vector Biolabs and supplied at 2.6 × 1013 GC/ml and 6.0 × 1013
GC/ml, respectively. For systemic infection, AAV viruses were diluted in PBS, each
mouse received 1 × 1011 GC in 100 µl via tail vein injection at 4–7 weeks of age.
Quantitative reverse transcription PCR. Total RNA was isolated using TRIzol
Reagent (Thermo Fisher, 15596-018) following manufacturers instructions. cDNA
was synthesised from 1 µg of RNA using the High-Capacity cDNA Reverse
Transcription Kit with RNase Inhibitor (Thermo Fisher, 4374966) following
manufacturers instructions. Quantitative reverse transcription PCR (qRT-PCR)
reactions were performed on a Applied Biosystems QuantStudio 5 Real-Time PCR
System using Fast SYBR Green Master Mix (Thermo Fisher, 4385612), following
manufacturers instructions. Primer sequences in Supplementary Table 1. Expres-
sion is normalised to Gapdh and Actin.
Flow cytometry analysis of DNA content. For MEFs: Cells were trypsinised,
washed in PBS and fixed in 70% ethanol overnight. Fixed cells were rehydrated,
washed in PBS, treated with RNase A (10 µg) and PI (5 µg), and analysed by Flow
cytometry using a BD Accuri C6 flow cytometer. For each sample, at least 10,000
events were recorded and analysed using FlowJo software (Tree Star).
Fix-dissociation of cardiomyocytes. Whole hearts were isolated from mice and
washed in PBS followed by fixation in 1% PFA overnight at room temperature
with agitation. The following day hearts were washed four times in PBS. Hearts
were cut into 1–2 mm3 pieces and incubated with 0.5 U/mL collagenase B (Roche
#11088807001) in 0.2% NaN3/PBS and left to oscillate at 1000 rpm at 37 °C. Every
12 h, the cardiomyocyte supernatant was collected and stored at 4 °C in 0.2%
NaN3/FBS. Once dissociation was complete (~8 days) cells were centrifuged at
1000 × g for 3 min, washed twice in PBS and stored in 0.2% NaN3/PBS at 4 °C. All
of the following incubations were carried out at room temperature. A total of
500,000 cardiomyocytes were incubated with blocking buffer (4% BSA, +0.2%
Triton X-100, +1 mM EDTA and +0.02% sodium azide) and agitated (1000 rpm)
at room temperature for 3 min. Cells were then re-suspend in primary antibodies
(Cardiac Troponin T (13-11; Thermo Fisher, MA5-12969; 1:100, p-H3 (Millipore,
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Fig. 9 Overexpression of Cyclin T1 in the adult heart facilitates Myc-driven proliferation of adult cardiomyocytes. a Immunofluorescent staining of
cardiac troponin, p-H3,Ki67, PCM1, wheat germ agglutinin (WGA) and aurora B in control (R26LSL-CMER/+; no cre) and Myh6-Cre; R26LSL-CMER/+
(R26LSL-CMER/+; cre+) adult mouse heart isolated 4 weeks post systemic infection with an adeno-associated virus encoding Ccnt1 (AAV9-Ccnt1) and
48 h post administration of tamoxifen. Representative images based on analysis of five independent mice. Scale bars represents 10 μm (aurora B)
and 50 μm (all others). b Quantification of p-H3-positive nuclei percentage in control (R26LSL-CMER/+; no cre, n= 9) and Myh6-Cre; R26LSL-CMER/+
(R26LSL-CMER/+; cre+, n= 7) adult mouse heart isolated 4 weeks post systemic infection with an adeno-associated virus encoding Ccnt1 (AAV9-Ccnt1)
and 48 h post administration of tamoxifen. Means are taken from five images per mouse; Mean and s.e.m shown. Unpaired t-test; no cre vs cre+ P <
0.0001. c The weight (mg) of hearts isolated from control (R26LSL-CMER/+; no cre, n= 9 48 h, n= 5 72 h) and Myh6-Cre; R26LSL-CMER/+ (R26LSL-CMER/+;
cre+, n= 7 48 h, n= 6 72 h) adult mouse heart 4 weeks post systemic infection with an adeno-associated virus encoding Ccnt1 (AAV9-Ccnt1) and 48
and 72 h post administration of tamoxifen, expressed as fold change over the length (mm) of a tibia isolated from the same mouse. Mean and s.e.m
shown. One-way ANOVA with Tukey’s multiple comparisons test; no cre vs cre+: *P= 0.05 (48 h), ***P= 0.001 (72 h). Replicate samples are derived
from independent mice. d Image of the whole heart and a tibia from control (R26LSL-CMER/+; no cre) and Myh6-Cre; R26LSL-CMER/+ (R26LSL-CMER/+; cre+)
adult mouse heart isolated 4 weeks post systemic infection with an adeno-associated virus encoding Ccnt1 (AAV9-Ccnt1) and 72 h post administration of
tamoxifen. Scale bar represents 10 mm. Representative images based on analysis of 11 independent mice. e Quantification of the number and size of
cardiomyocytes from control (R26LSL-CMER/+; no cre, n= 5) and Myh6-Cre; R26LSL-CMER/+ (R26LSL-CMER/+; cre+, n= 6) adult mouse heart isolated
4 weeks post systemic infection with an adeno-associated virus encoding Ccnt1 (AAV9-Ccnt1) and 72 h post administration of tamoxifen. Mean and s.d
shown. One-way Mann–Whitney test; no cre vs cre+ **P= 0.0043. Replicate samples are derived from independent mice. Source data are provided as
a Source Data file.
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1:400))) and incubated with agitation for 1 h. After two washes in blocking buffer,
secondary antibodies (Alexa Fluor 488 Goat Anti-mouse IgG (H+L; Life Tech-
nologies, A11008)) were incubated together with Hoechst and agitated for 1 h at
room temperature. Following two washes in blocking buffer, cells were re-suspend
in blocking buffer, and either spun onto slides and mounted for imaging or ana-
lysed by flow cytometry. Cardiomyocyte length and width was measured using
ImageJ software on images over-exposed for Cardiac Troponin T. A mean cell size
for each heart was determined from measurements of >13 individual cells. Flow
cytometry was performed on a BD LSRFortessa and analysed using FlowJo software
(Tree Star).
Immunoblotting. Snap frozen animal tissues were ground on liquid nitrogen.
Isolated cells were directly lysed on cell culture dishes and proteins extracted in
buffer containing 1% SDS, 50 mM Tris pH 6.8 and 10% glycerol on ice for 10 min.
Lysates were boiled for 10 min, followed by sonication (Bioruptor, Diagenode) for
15 min on ice. Total protein (50 µg) was electrophoresed on an SDS–PAGE gel and
transferred onto immobilon-P (Millipore) membranes. These were then blocked in
5% non-fat milk and incubated with primary antibodies overnight at 4 °C. Sec-
ondary antibodies were applied for 1 h followed by chemiluminescent visualisation
(Thermo Scientific, 32106 or Millipore, WBKLS0500). Immunoblots were devel-
oped on Fuji RX X-ray film, scanned on an Epson Perfection V500 Photo flatbed
scanner. Images were cropped using Adobe Photoshop but otherwise unprocessed.
Primary antibodies: GAPDH (D16H11) XP® (Cell Signaling Technology, 5174,
used at 1:5000), β-actin (AC-15; Santa-Cruz Biotechnology, sc-69879, used at
1:5000), α-tubulin antibody (DM1A; Santa-Cruz Biotechnology, sc-32293, used at
1:5000), Myc (Y69; Abcam, ab32072, used at 1:10,000), Rpb1 CTD (4H8; Cell
Signaling Technology, 2629, used at 1:2500), phospho-Rpb1 CTD (Ser2; E1Z3G;
Cell Signaling Technology, 13499, used at 1:2500), phospho-Rpb1 CTD (Ser5;
D9N5I; Cell Signaling Technology, 13523, used at 1:2500), CDK9 (C12F7; Cell
Signaling Technology, 2316, used at 1:1000), Cyclin T1 (D1B6G; Cell Signaling
Technology, 81464, used at 1:1000), LARP7 (Abcam, ab134746, used at 1:1000),
anti-rabbit IgG HRP (Sigma, A0545, used at 1:10,000) and anti-mouse IgG HRP
(Sigma, A0944, used at 1:10,000). Sample loading was normalised for equal protein
content. Expression of GAPDH or α-tubulin is included as a confirmation of
efficiency of protein isolation and comparable loading between individual tissue
samples. Where necessary a composite figure was generated from the same samples
loaded across multiple blots and a representative image of GAPDH is shown,
Fig. 5a and Supplementary Fig. 5a.
Immunohistochemistry. Immunohistochemistry was performed on 4 µm sections.
Sections were de-paraffinized and rehydrated. Antigens were retrieved by boiling in
10 mM citrate buffer (pH 6.0) for 10 min. Endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide for 30 min. Sections were then treated with
rabbit VECTASTAIN Elite ABC horseradish peroxidase kit (Vector Laboratories,
PK-6101) following the manufacturers protocols with all incubations were carried
out at room temperature. Briefly, sections were blocked in normal goat serum for
20 min, followed by 1 h incubation in primary antibody. Sections were then washed
three times in PBST, and incubated for 30 min in secondary antibody, sections
were then washed again in PBST and then incubated in ABC complex. Sections
were developed in DAB (3,3′-diaminobenzidine) for 5 min, counterstained in
haematoxylin, dehydrated and mounted in DPX. Staining was imaged on a Zeiss
Axio Imager using the Zeiss AxioVision 4.8 software using the AutoLive setting
and interactive white balance. Quantification was performed by counting number
of cells per field of view for five images per organ/mouse, the mean of five raw
counts was calculated and is represented by each data point per graph.
Primary antibodies; anti-Ki67 (SP6; Thermo Scientific, RM-9106; 1:200), anti-
phospho-Histone H3 (Ser10; Merck Millipore, 06-570; 1:1250) and anti-Cyclin T1
(AbCam, ab238940; 1:500).
Immunoflorescence. Immunoflorescence was performed on 4 µm sections. Sec-
tions were de-paraffinized and rehydrated. Antigen retrieval was performed by
boiling in 10 mM citrate buffer (pH 6.0) for 10 min. For BrdU staining, DNA was
denatured with 2N HCL, 0.2% triton X for 10 mins at 37 °C. Sections were blocked
in 2.5% goat serum (from number), 1% BSA in PBST for 20 mins at room tem-
perature. Primary antibody, made up in blocking buffer, was added for 1 h at room
temperature, followed by PBST washes and secondary antibodies added for 1 h at
room temperature. Nuclei were visualised using Hoechst (Sigma, 861405) and
sections mounted in prolong gold (Thermo Fisher, P36930). Antibodies: anti-
phospho-Histone H3 (Ser10; Merck Millipore, 06-570: Antibody; 1:500), cardiac
troponin T (13-11; Thermo Fisher, MA5-12969; 1:100), anti-BrdU (BU1/75
(ICR1)) antibody (Abcam, ab6326, 1:200), anti-aurora B antibody (Abcam, ab2254;
1:200), anti-PCM1 (SigmaAldrich, HPA023370, 1:100), anti-Ki67 (SolA15; Thermo
Fisher, 1:100), Alexa Fluor 555 goat anti-rabbit IgG (H+L; Life Technologies,
A21428), Alexa Fluor 555 goat anti-mouse IgG (H+L; Life Technologies, A21422),
Alexa Fluor 555 goat anti-rat IgG (H+L; Life Technologies, A21434), Alexa Fluor
488 goat anti-rabbit IgG (H+L; Life Technologies, A11008), Alexa Fluor 488 goat
anti-rat IgG (H+L; Life Technologies, A11006), Alexa Fluor 350 goat anti-mouse
(H+L; Life Technologies A11045), wheat germ agglutinin, Alexa Fluor™ 488 con-
jugate (Thermo Fisher, W11261).
Southern blotting. DNA (≥10 µg) was digested overnight with appropriate
restriction enzymes and run on a 0.8% agarose gel to separate fragments. Gels were
subject to depurination and neutralisation before transferring DNA to Hybond-XL
membrane (RPN203S, GE Healthcare Amersham) overnight by capillary action.
The membrane was then washed and dried at 80 °C for 2 h. αP32–dCTP probes
were labelled using Prime-It® II Random Primer Labelling Kit (300385, Agilent)
and purified with Illustra ProbeQuant™ G-50 Micro columns (28-9034-08, GE
Healthcare Amersham). Following pre-hybe for 1–2 h in Rapid-hyb™ Buffer
(RPN1636, GE Healthcare Amersham), the membrane was hybridised with the
probe for at least 5 h, washed, exposed to Fuji RX X-ray film and the film scanned
on an Epson Perfection V500 Photo flatbed scanner.
Transmission electron microscopy. Day 15 R26CMER/+ mouse heart was cut into
1 mm2 pieces and fixed overnight in fresh 2.5% glutaraldehyde/PBS solution
(Sigma, G7651), followed by three washes in PBS. Samples were then placed in
fresh fix and irradiated for 6 min at 80W under vacuum in a Pelco Biowave (Ted
Pella In, Redding, CA). Fixed tissue was then stained with 3% potassium ferri-
cyanide and 2% osmium tetroxide in 0.1 M cacodylate buffer for 30 min,
then washed three times in distilled water and incubated in 1% thiocarbohydrazide
for 30 min at room temperature. Samples were then washed three times in distilled
water and immersed in 2% osmium tetroxide for 30 min at room temperature, then
again washed three times in distilled water. Samples were contrasted with 1%
aqueous uranyl acetate for 30 min at 4 °C and washed three times in distilled water.
A solution of 0.06% lead nitrate was prepared by dissolving in aspartic acid (pH
5.5) at 60 °C, which was then filtered and added to samples for 20 min at 60 °C
before washing three times with distilled water at room temperature. Pieces of
tissue underwent serial dehydration by immersing in each increasing ethanol
concentration twice (30%, 50%, 70%, 90% and 100%) and irradiating for 40 s at
250W in a Pelco microwave. Samples were then infiltrated with increasing con-
centrations of epon LX112 resin (25%, 50% and 75%) in ethanol for 3 min at 250W
under vacuum in a Pelco microwave, then twice in 100% resin before polymerising
at 60 °C overnight79. Samples were analysed on a Apreo FESEM equipped with a
VolumeScope serial block face system and MAPS software (Thermo Fisher) with a
slice thickness of 100 nm. Datasets were aligned, segmented and visualised in Imod
(Bio3D) and Chimera (UCSF) software.
3View EM stacks were assembled and 3D modelling of structures was
performed in IMOD 3D reconstruction and visualisation software (University of
Colorado, Boulder).
ChIP sequencing. Mouse tissue was harvested from mice, washed in PBS and cut
into small 2–3 mm pieces with a scalpel blade. Tissue was then fixed in 1% for-
maldehyde/PBS for 15 min, washed in PBS three times, snap frozen and stored at
−80 °C until further processing. Upon thawing, tissue was incubated in 125 mM
glycine (5 min, room temperature), washed in PBS and nuclei prepared on ice
using a dounce homogeniser. All following steps were performed on ice. Nuclei
were washed in PBS, resuspended in ChIP buffer (4 ml of buffer per 0.5 ml of
tissue; 100 mM NaCl, 133 mM Tris pH 8.0, 5 mM EDTA, 0.02% NaN3, 0.67% SDS
and 1.67% Triton X-100) supplemented with protease inhibitors (Complete Pro-
tease Inhibitor Cocktail Tablets, Roche) and phosphatase inhibitors (50 mM NaF,
1 mM β-GP and 1mM NaV). Chromatin was sonicated to an average length of
300 bp, pre-cleared twice with protein G-sepharose beads, pre-blocked with 0.5%
Escherichia. coli tRNA (Sigma) and 0.5% BSA (ref. 80). In this study, the following
antibodies were used: Myc N262 (Santa Cruz, sc-764×), RNA PolII N20 (Santa
Cruz, sc-899×). A total of 10 µg of antibodies were incubated overnight with 500 µl
of chromatin (+500 µl of ChIP buffer to each a volume of 1 ml per reaction).
Blocked protein G-sepharose beads were added, incubated for 2–3 h and washed as
follows: three times with mixed micelle buffer (150 mM NaCl, 20 mM Tris pH 8.1,
5 mM EDTA, pH 8.0, 5.2% sucrose, 0.02% NaN3, 1% Triton X-100 and 0.02%
SDS), 2x with buffer 500 (50 mM HEPES pH 7.5, 0.1% sodium deoxycholate, 1 mM
EDTA, 500 mM NaCl, 1% Triton X-100 and 0.02% NaN3), two times with LiCl/
detergent buffer (10 mM Tris pH 8.0, 0.5% sodium deoxycholate, 1 mM EDTA,
250 mM LiCl, 0.5% NP-40 and 0.02% NaN3) and once with TE. DNA was de-
crosslinked overnight (2% SDS in TE, 65 °C), purified using QiaQuick columns
(Qiagen) and quantified using Qbit (Thermo Fisher). A total of 2–5 ng of ChIP
DNA were used for ChIP-seq library preparation, using the TruSeq ChIP Library
Preparation Kit (Illumina), following manufacturers instructions.
RNA sequencing. Total RNA from tissues was purified using TRIzol (Invitrogen).
Briefly, tissue was homogenised in Trizol (Invitrogen) and chloroform was added.
After centrifugation, RNA was purified using RNeasy Mini columns (Qiagen)
according to the manufacturer’s protocol, including the on column DNaseI
digestion step. Alternatively, total RNA was purified using PureLink RNA Mini Kit
(Thermo Scientific) together with on column DNA digestion using PureLink
DNase (Thermo Scientific). Then 1–5 µg of purified RNA was treated with Ribo-
zero rRNA removal kit (Illumina) and ethanol precipitated. RNA quality and
removal of rRNA were checked with the Agilent 2100 Bioanalyser (Agilent
Technologies). Libraries for RNA-seq were then prepared with the TruSeq RNA
Sample Prep Kits v2 (Illumina) or NEBNext® Ultra™ II DNA Library Prep Kit for
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Illumina (NEB), following manufacturers instructions starting from the RNA
fragmentation step.
RNA-seq sample processing and analysis. Adult tissues: Sequence reads were
aligned to the mm9 mouse reference genome using TopHat aligner (version 2.0.8).
In case of duplicated reads, only one read was kept. FeatureCounts software was
used to associate read counts to genes (http://bioinf.wehi.edu.au/featureCounts/).
Exon reads per kilobase per million mapped reads (eRPKM) defined gene expres-
sion using total library size as the number of reads aligned on exons. We applied a
filter for a minimum expression level average eRPKM > 3.5 and Log2FC > 0.5, DEGs
were identified using the Bioconductor package DESeq2 (ref. 81).
AAV infected and day 15 heart+mouse samples: Sequence reads were adaptor
trimmed using Cutadapt82 (version 1.11) and aligned using BWA aln for short
reads83 (version 2.5.2a) to the GRCm38 (mm10) assembly with the gene, transcript
and exon features of the Ensembl (release 70) gene model. Expression was
estimated using RSEM84 (version 1.2.30). Transcripts with zero read counts across
all samples were removed prior analysis. Normalisation of RSEM expected read
counts was performed by dividing by million reads mapped to generate counts per
million, followed by the trimmed mean of M-values method from the edgeR
package85,86. Differential expression analysis was performed using edgeR.
ChIP-seq data analysis. Data were generated and processed by aligning sequence
reads to the mm9 genome with the BWA aligner using default settings. Peaks were
called using the MACS software (v2.0.9)87. Normalised read counts within a
genomic region were determined as the number of reads per million of library
reads (total number of aligned reads in the sequencing library). Peak enrichment
was determined as log2 (Peakw/Nc—inputw/Ni), where Peakw is the read count on
the enriched region and inputw the read count on the same region in the corre-
sponding input sample, Nc is the total number of aligned reads in the ChIP sample
and Ni is the total number of aligned reads in the input sample. Promoter peaks
were defined as all peaks with at least one base pair overlapping with the interval
between −2 kb to +1 kb from the nearest TSS. Myc-binding peaks called in the
heart but not in the liver were annotated as heart specific, and peaks called in the
liver but not in the heart were annotated as liver specific. Myc-binding peaks
identified in both tissues, heart and liver, were annotated as common Myc
binding sites.
For the analysis of chromatin accessibility, regulatory elements and
transcriptional activity, genomic regions of promoter Myc binding sites in liver and
heart were extracted 6 kb around the peak centre. Read coverage of the 6 kb Myc-
bound genomic regions, were extracted from the alignment bam files using the
Genomation R package88. To overlap Myc peaks with chromatin accessibility and
active promoter histone marks, we extracted publicly available data from 8 week
adult C57BL/6 liver and heart tissue from ENCODE (DNaseI: http://genome.ucsc.
edu/cgi-bin/hgFileUi?db=mm9&g=wgEncodeUwDnase, ChIP: http://genome.
ucsc.edu/cgi-bin/hgFileUi?db=mm9&g=wgEncodeLicrHistone, Download: 01/08/
2018). Specifically, chromatin accessibility was ascertained using a DNaseI
hypersensitivity assay, and active promoters were identified based on H3K27ac and
H3K4me3 ChIP sequencing. Read coverage of the 6 kb Myc-bound genomic
regions were extracted using the genomation R package from bigwig files generated
by ENCODE. For each ChIP (Myc, PolII, H3K27ac, H3K4Me1 and H3K4me3) and
DNaseI experiment, read coverage of the 6 kb regions were binned into 100 equally
sized bins with the maximum counts used for smoothing windows. Each
experiment’s smoothed read coverage was visualised in a heatmap with
independent colour scales to account for differences in experimental protocols,
processing and tissue. Genomic regions were clustered based on whether Myc
binding was specific for heart, liver or common to both tissues.
Statistical analysis. Pipelines for primary analysis (filtering and alignment to the
reference genome of the raw reads) and secondary analysis (expression quantifi-
cation, differential gene expression and peak calling) have been integrated in the
HTS-flow system89. Bioinformatic and statistical analysis were performed using R
with Bioconductor packages and comEpiTools packages90,91. Motif analysis was
performed using CentriMo software92. Intron analysis was performed with the
INSPEcT tool93,94. Gene lists from RNA and ChIP sequencing were analysed in
Enrichr95. Statistical analyses for IHC and qRT-PCR were performed using
GraphPad Prism v6.0d (GraphPad Software, Inc., San Diego, CA, USA) as indi-
cated with P ≤ 0.05 considered to be statistically significant. Venn diagrams were
draw in the interactive tool Venny [https://bioinfogp.cnb.csic.es/tools/venny/index.
html].
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All datasets generated in this study, including Myc ChIP sequencing, RNA PolII ChIP
sequencing and RNA sequencing, have been deposited in ArrayExpress (www.ebi.ac.uk/
arrayexpress) under accession codes; E-MTAB-7592, E-MTAB-7593, E-MTAB-7595, E-
MTAB-8462, E-MTAB-8515 and E-MTAB-7636. The source data underlying Figs. 1a, c
d, 4a, 5a–e, 6a, b, d, 7c, d, 8a–c, 9b, c, e and, Supplementary Figs. 1b–d, f, h, 2a, 4a, b,
5a–f, 6a, b, d, 7c, 8a and 9a, d, e are provided as a Source Data file. Further information
and requests for resources and reagents should be directed to, and will be fulfilled by,
Gerard Evan (gie20@cam.ac.uk). Requests regarding AZ5576 should be directed to
AstraZeneca PLC.
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